MSD’s 2026 sales forecast falls short amid patent losses despite strong Q4
Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more…
News
SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal
Aquestive receives FDA CRL for Anaphylm allergic reaction treatment
Eli Lilly selects Pennsylvania for $3.5bn manufacturing site of obesity drugs
Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data
CHMP grants positive opinion for J&J’s Akeega use
CIRM unveils RAPID funding programme for rare diseases
FDA’s new scheme to boost US manufacturing commences despite uncertainty
